Literature DB >> 7257088

Hypercalcemia associated with an adenocarcinoma derived from the apocrine glands of the anal sac.

D J Meuten, B J Cooper, C C Capen, D J Chew, G J Kociba.   

Abstract

Clinical, gross, and light microscopic findings are described for 36 dogs, 33 females and three males, with adenocarcinomas arising from the apocrine glands of the anal sac. All tumors had light microscopic features of malignancy and 22 of 23 metastasized to iliac and lumbar lymph nodes. Nine dogs had disseminated metastases, but bone metastases were found in only one dog. Differentiated neoplasms formed secretory acini and tubules lined by tall columnar or cuboidal epithelium. Most neoplasms were histologically bimorphic, with glandular areas and solid nests. Parathyroid glands were atrophic. Hypercalcemia (mean = 16.1 mg/dl) was present in 20 of 22 dogs (90%) and hypophosphatemia (mean = 3.2 mg/dl) in 12 of 17 (71%). Remission of hypercalcemia by tumor ablation and recurrence of hypercalcemia with tumor regrowth suggested that the tumor produced a substance that caused hypercalcemia. This unique clinicopathologic syndrome is characterized by hypercalcemia in old, predominantly female, dogs with an adenocarcinoma arising from the apocrine glands of the anal sac.

Entities:  

Mesh:

Year:  1981        PMID: 7257088     DOI: 10.1177/030098588101800405

Source DB:  PubMed          Journal:  Vet Pathol        ISSN: 0300-9858            Impact factor:   2.221


  8 in total

1.  Metastatic anal sac adenocarcinoma in a dog presenting for acute paralysis.

Authors:  Brigitte A Brisson; Douglas P Whiteside; David L Holmberg
Journal:  Can Vet J       Date:  2004-08       Impact factor: 1.008

2.  Hypercalcemia of malignancy: Hypercalcemia associated with an adenocarcinoma of the apocrine glands of the anal sac.

Authors:  D J Meuten; C C Capen; G J Kociba; B J Cooper
Journal:  Am J Pathol       Date:  1982-09       Impact factor: 4.307

3.  Adenylate cyclase-stimulating, bone-resorbing and B TGF-like activities in canine apocrine cell adenocarcinoma of the anal sac.

Authors:  E C Weir; M Centrella; R E Matus; M L Brooks; T Wu; K L Insogna
Journal:  Calcif Tissue Int       Date:  1988-12       Impact factor: 4.333

4.  Evaluation of adjuvant carboplatin chemotherapy in the management of surgically excised anal sac apocrine gland adenocarcinoma in dogs.

Authors:  R M Wouda; J Borrego; N S Keuler; T Stein
Journal:  Vet Comp Oncol       Date:  2013-10-24       Impact factor: 2.613

5.  Ultrastructural evaluation of adenocarcinomas derived from apocrine glands of the anal sac associated with hypercalcemia in dogs.

Authors:  D J Meuten; C C Capen; G J Kociba; D J Chew; B J Cooper
Journal:  Am J Pathol       Date:  1982-05       Impact factor: 4.307

6.  Evaluation of expression and function of vascular endothelial growth factor receptor 2, platelet derived growth factor receptors-alpha and -beta, KIT, and RET in canine apocrine gland anal sac adenocarcinoma and thyroid carcinoma.

Authors:  Bridget K Urie; Duncan S Russell; William C Kisseberth; Cheryl A London
Journal:  BMC Vet Res       Date:  2012-05-25       Impact factor: 2.741

7.  Utility of Computed Tomography versus Abdominal Ultrasound Examination to Identify Iliosacral Lymphadenomegaly in Dogs with Apocrine Gland Adenocarcinoma of the Anal Sac.

Authors:  S Palladino; M A Keyerleber; R G King; K E Burgess
Journal:  J Vet Intern Med       Date:  2016-10-24       Impact factor: 3.333

8.  Apocrine gland anal sac adenocarcinoma with perineural metastasis in a cat.

Authors:  Joseph S Raleigh; Matthew R Lanza; James A Perry
Journal:  JFMS Open Rep       Date:  2018-12-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.